Genmab says head and neck cancer drug cuts death risk by 50% with Merck’s Keytruda

What happened: Genmab said its bispecific antibody petosemtamab, combined with Merck's Keytruda, cut mortality risk by 50% in certain head and neck cancer patients. Key numbers: Mortality risk reduced by 50%. Genmab ADRs rose nearly 15% on Wednesday. Why it matters: The data lifted Genmab's ADRs sharply, pointing to investor reaction to the combination therapy's survival benefit in head and neck cancer. Coverage: 3 outlets in 24h

Genmab said its bispecific antibody petosemtamab, combined with Merck's Keytruda, cut mortality risk by 50% in certain head and neck cancer patients.

The data lifted Genmab's ADRs sharply, pointing to investor reaction to the combination therapy's survival benefit in head and neck cancer.